Parenteral nutrition

Intravenous (IV) Solutions Global Strategic Research Report 2024-2030: Developed Economies Lead, Developing Regions to Propel Future Growth - ResearchAndMarkets.com

Retrieved on: 
Mercredi, mai 22, 2024
Medical Supplies, Health, Nutritional science, COVID-19, Intravenous therapy, TPN, Growth, Ageing, Sodium chloride, Parenteral nutrition, Lead, Palladium

The "Intravenous (IV) Solutions - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Intravenous (IV) Solutions - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The competition in the intravenous (IV) solutions market is intense, with global key competitors' percentage market share estimated for 2023 highlighting the leading players.
  • This introduction to IV solutions covers the various types, including saline solutions, dextrose solutions, and more specialized formulations like Total Parenteral Nutrition (TPN) and single-dose amino acid solutions.
  • Developed economies currently lead in market share, but developing regions are expected to drive future growth due to expanding healthcare infrastructure and rising medical needs.

Baxter Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication

Retrieved on: 
Lundi, mai 13, 2024
Medical Supplies, Women, FDA, Baby, Maternity, Fitness & Nutrition, Biotechnology, General Health, Pharmaceutical, Consumer, Health, Patient, Oleic acid, Route of administration, Risk, Olive oil, Tubing (recreation), Parenteral nutrition, Soybean oil, Chinese, Growth, Baxter International, Malnutrition, U.S. FDA, Dietary supplement

Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, today announced U.S. FDA approval of an expanded indication for Clinolipid (Lipid Injectable Emulsion) to be used in pediatric patients, including preterm and term neonates.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, today announced U.S. FDA approval of an expanded indication for Clinolipid (Lipid Injectable Emulsion) to be used in pediatric patients, including preterm and term neonates.
  • Clinolipid is Baxter’s proprietary mixed oil lipid emulsion that is used to provide calories and essential fatty acids in parenteral (intravenous) nutrition (PN) when oral or enteral nutrition is not possible, insufficient or contraindicated.
  • Clinolipid has been available in the U.S. for adults since 2019 and is now available for use in all ages.
  • Over the last several years, clinical practice has shifted away from using 100 percent soybean oil lipid emulsions – which was the standard of care for decades – to mixed lipid emulsions.

Pediatric Academic Societies Meeting Includes Symposium on Cost-Effectiveness of Implementing Exclusive Human Milk-Based Nutrition for Premature Infants

Retrieved on: 
Vendredi, mai 3, 2024
NICU, Hospital, Health, Adolescence, Infant, Length of stay, BMBF, Parenteral nutrition, Patient, VLBW, Hospice and palliative medicine, Child, FAAP, PAS

DUARTE, Calif., May 3, 2024 /PRNewswire/ -- Prolacta Bioscience, the world's leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants, announced today that Dr. Rangasamy Ramanathan, professor of pediatrics division chief, division of neonatal medicine, Los Angeles General Medical Center and PIH Good Samaritan Hospital, will present published data on the financial and clinical benefits of implementing an Exclusive Human Milk Diet (EHMD) for very low birth weight (VLBW) infants during the 2024 Pediatric Academic Societies (PAS) Meeting on Saturday, May 4, 6:30-8 p.m. ET, in Toronto.

Key Points: 
  • PAS connects thousands of leading pediatric researchers, clinicians, and medical educators worldwide to advance scientific discovery and promote innovation in child and adolescent health.
  • "We saw significant reductions in length of stay and days on parenteral nutrition, which directly translated to substantial cost savings for our NICU."
  • "We encourage PAS attendees to attend the symposium to learn more about the clinical and financial benefits of EHMD implementation."
  • Extensive real-world data affirm EHMD adoption enables critical health improvements for premature infants and major cost reductions for hospitals.

Soleo Health Unveils Pharmacy in Jackson, MS; Marks Pharmacy Entry Into State

Retrieved on: 
Lundi, avril 29, 2024
Professional Services, Other Science, Research, Science, Practice Management, Nursing, Medical Supplies, Other Health, Managed Care, FDA, General Health, Diabetes, Radiology, Pharmaceutical, Oncology, Medical Devices, Infectious Diseases, Hospitals, Software, Genetics, Fitness & Nutrition, Clinical Trials, Cardiology, Biotechnology, AIDS, Technology, Health, Surgery, Insurance, Ulcerative colitis, Pharmacy, Crohn's disease, Immunodeficiency, Graves' ophthalmopathy, AIC, Alzheimer's disease, Parenteral nutrition, Patient, ALS, Rheumatoid arthritis, Hattiesburg, Mississippi, Medical device

Soleo Health , a national provider of complex specialty pharmacy services, announced today the opening of its latest pharmacy and ambulatory infusion center (AIC) in Ridgeland, Mississippi.

Key Points: 
  • Soleo Health , a national provider of complex specialty pharmacy services, announced today the opening of its latest pharmacy and ambulatory infusion center (AIC) in Ridgeland, Mississippi.
  • The new Soleo Health Jackson location, at 1250 E. County Line Road, Ridgeland, Mississippi, 601.427.4510, is a state-of-the-art pharmacy supporting patients in their homes or at its ambulatory infusion center.
  • Soleo Health Jackson specializes in providing biologic and infusion therapies for patients with complex, rare and ultra-rare diseases and autoimmune disorders.
  • “Soleo Health identified an opportunity to expand its reach in Mississippi by bringing its complex specialty pharmacy services to the marketplace.

$1.25 Billion Parenteral Nutrition Bags Markets by Chamber Type, Consumer, End User - Global Forecast to 2031 - ResearchAndMarkets.com

Retrieved on: 
Vendredi, avril 19, 2024
Seniors, Pharmaceutical, Health, Parenting, Children, Baby, Maternity, Consumer, Fitness & Nutrition, Irritable bowel syndrome, Dicarboxylic acid, DSM-IV codes, Risk, Hospital, Route of administration, Indigestion, Parenteral nutrition, Prevalence, Rome process, Vitamin, Electrolyte, Incidence, Patient, Developed country, Carbohydrate, Malnutrition, Pharmacy, Element, Lipid, Growth, Infection, Pet industry

The "Parenteral Nutrition Bags Market by Chamber Type (Single-Chamber Bags, Dual-Chamber Bags, Multi-Chambered Bags), Consumer (Adults, Children), End User (Healthcare Facilities, Pharmacies & Compounding Service Providers) - Global Forecast to 2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Parenteral Nutrition Bags Market by Chamber Type (Single-Chamber Bags, Dual-Chamber Bags, Multi-Chambered Bags), Consumer (Adults, Children), End User (Healthcare Facilities, Pharmacies & Compounding Service Providers) - Global Forecast to 2031" report has been added to ResearchAndMarkets.com's offering.
  • The global parenteral nutrition bags market is projected to reach $1.25 billion by 2031, at a CAGR of 6.6% from 2024 to 2031.
  • The lack of awareness regarding parenteral nutrition in developing countries is a major challenge impacting the growth of the parenteral nutrition bags market.
  • Among chamber types, in 2024, the single-chamber parenteral nutrition bags segment is expected to account for the largest share of the parenteral nutrition bags market.

Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition

Retrieved on: 
Vendredi, avril 5, 2024
Choline, Plasma, Liver, Nutritional science, Route of administration, Liver disease, Steatosis, Short bowel syndrome, Metabolism, Patient, Choline chloride, Cancer, ESPEN, Parenteral nutrition, Adolescence, Liver injury, Hepatology, Tubing (recreation), Fibrosis, Guideline, Society, Therapy, Copenhagen University Hospital, Safety, Pharmacokinetics, PN, FDA, ASPEN, Rigshospitalet, Food, Feeding tube, Extractive metallurgy

IV Choline Chloride has the potential to become the first FDA-approved IV formulation of choline for the 40,000 PN patients in the U.S.

Key Points: 
  • IV Choline Chloride has the potential to become the first FDA-approved IV formulation of choline for the 40,000 PN patients in the U.S.
  • The Company plans to advance the development of IV Choline Chloride as a source of choline for adult and adolescent patients on long-term PN.
  • The FDA has granted IV Choline Chloride Orphan Drug Designation for the prevention of choline deficiency in PN patients.
  • “We look forward to advancing the clinical development of IV Choline Chloride, which we believe has the potential to become the first FDA approved IV choline therapy for patients dependent on PN.

Orphan designation: Alisitol, retinol palmitate, zinc gluconate Treatment of microvillus inclusion disease, 13/11/2020 Positive

Retrieved on: 
Mardi, avril 9, 2024
Eurostat, Civil service commission, Salt, Diagnosis, Absorption, Microvillous inclusion disease, DSM-IV codes, Nutrient, Cell, Patient, Committee, Weight loss, Knowledge, Regulation, Food, EMA, IRIS, Noetics, Parenteral nutrition, Diarrhea, European, Malnutrition, COMP, Dehydration, Water, Safety, European Commission, Liver, Medicine, Pharmaceutical industry

Orphan designation: Alisitol, retinol palmitate, zinc gluconate Treatment of microvillus inclusion disease, 13/11/2020 Positive

Key Points: 


Orphan designation: Alisitol, retinol palmitate, zinc gluconate Treatment of microvillus inclusion disease, 13/11/2020 Positive

Global Enteral Feeding Devices Market Insights 2024-2029 with Avanos Medical and B. Braun Melsungen Leading through Substantial R&D Investments - ResearchAndMarkets.com

Retrieved on: 
Mardi, mars 12, 2024
Health, Medical Devices, Other Health, Hospital, Cardiology, Incidence, Enterostomy, Neurology, Conditional sentence, Growth, Prevalence, Obesity, Esophagitis, DSM-IV codes, Patient, Research, GI, Cancer, HEN, Crohn's disease, Ageing, Parenteral nutrition, Syringe, Diet, Gastrointestinal disease, Investment, Malnutrition, Safety, IBS, Dysphagia, USD, Avanos Medical, Tubing (recreation), Pediatrics, PEG

The enteral feeding devices market features diverse players, from well-established giants to dynamic emerging entities, focusing on innovation and strategic growth.

Key Points: 
  • The enteral feeding devices market features diverse players, from well-established giants to dynamic emerging entities, focusing on innovation and strategic growth.
  • Leading firms such as Avanos Medical and B. Braun Melsungen distinguish themselves through substantial research and development (R&D) investments, forming strategic alliances, and initiatives to increase their market share.
  • The enteral feeding devices market is set for sustained growth, driven by healthcare advancements and a global emphasis on chronic disease management and nutritional support.
  • North America, particularly the United States and Canada, leads in the enteral feeding devices market.

Rising Aging Population and Changing Healthcare Preferences Fuel Home Infusion Therapy Market Growth - ResearchAndMarkets.com

Retrieved on: 
Lundi, novembre 6, 2023
Health, Other Health, Ageing, Fungal infection, Medicine, Prevalence, Endocrinology, Diabetes, Intake, Infusion pump, Quality of life, Parenteral nutrition, Cystic fibrosis, DSM-IV codes, Hospital, Patient, Patient safety, Vels Institute of Science, Technology & Advanced Studies, Cardiovascular disease, Pharmaceutical industry, Medical device, Growth

Home infusion therapy involves the intravenous or non-oral delivery of medication, offering convenience and 24/7 monitoring by healthcare professionals.

Key Points: 
  • Home infusion therapy involves the intravenous or non-oral delivery of medication, offering convenience and 24/7 monitoring by healthcare professionals.
  • Product: Infusion pumps dominate the home infusion therapy market due to their crucial role in ensuring accurate medication dosing and continuous monitoring.
  • The United States leads the home infusion therapy market, driven by an aging population with complex healthcare needs and a preference for home-based treatment options.
  • The U.S. market is positioned for ongoing growth due to a supportive regulatory environment and increasing awareness of the benefits of home infusion therapy.

CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition

Retrieved on: 
Jeudi, novembre 2, 2023
Acute lymphoblastic leukemia, CRAC, T16, Asparaginase, LA, Society, Severity, ASH, Pancreatitis, TPN, AAP, St. Jude Children's Research Hospital, Patient, ALL, Parenteral nutrition, ICU, Pharmaceutical industry

LA JOLLA, Calif., Nov. 2, 2023 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases, today announced that there will be a presentation of data from the initial cohort of the CRSPA study of Auxora™ (zegocractin) in asparaginase-induced pancreatic toxicity (AIPT) in a poster presentation at the 65th Annual American Society of Hematology (ASH) Meeting & Exposition being held December 9-12, 2023 in San Diego, CA.

Key Points: 
  • The presentation includes results from the first cohort consisting of nine patients from the CRSPA study.
  • ONCASPAR™ and RYLAYZE™), a nearly identical ALL treatment protocol as used in the CRSPA study.
  • Additionally, no CRSPA patients required total parenteral nutrition (TPN), compared to 68.8% in the historical matched control group.
  • Presentation Title: Zegocractin to Reduce the Severity of Asparaginase Associated Pancreatitis in Children with Acute Lymphoblastic Leukemia: Results of the Phase 1 Portion of the CRSPA Study